Background/Objectives: We assessed the frequency, timing and management of carbapenem-resistant Acinetobacter baumannii (CRAB) isolation and its association with in-hospital mortality in adults hospitalized with COVID-19. Methods: This retrospective single-center cohort study included all 395 adults admitted from 12 July to 25 September 2022. The primary analysis compared in-hospital mortality by CRAB isolation in the full cohort, with Firth-penalized adjustment for age and admission SpO2. Treatment and case-level data, complete for 95 chart-verified patients, were analyzed secondarily; isolates were classified by onset (NHSN criteria) and respiratory isolates adjudicated as infection or colonization. Results: CRAB was isolated in 33/395 patients (8.4%). Mortality was 36.4% (12/33) with CRAB isolation versus 11.6% (42/362) without (crude OR 4.35, 95% CI 1.81–10.02; adjusted OR 3.82, 95% CI 1.62–9.02). In the detailed-data subset (8/95 with CRAB), isolates were first detected on hospital days 2–6 and four were community-onset; four of seven respiratory isolates represented colonization. All eight received empirical carbapenem plus colistin after specimen collection, including full 9–10-day colistin-based courses in the four colonized patients. Conclusions: CRAB isolation was associated with higher in-hospital mortality after adjustment for baseline severity, but selective sampling precludes causal inference. Early detection suggests frequent carriage on admission; treatment of colonization was the main stewardship target, supporting admission screening and diagnostic stewardship.
No takes yet. Share an insight, caveat, or question.
Bujor et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: